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Abstract
In genome-wide association studies (GWAS) genetic markers are often ranked to select genes for
further pursuit. Especially for moderately associated and interrelated genes, information on genes
and pathways may improve the selection. We applied and combined two main approaches for data
integration to a GWAS for rheumatoid arthritis, gene set enrichment analysis (GSEA) and
hierarchical Bayes prioritization (HBP). Many associated genes are located in the HLA region on
6p21. However, the ranking lists of genes and gene sets differ considerably depending on the
chosen approach: HBP changes the ranking only slightly and primarily contains HLA genes in the
top 100 gene lists. GSEA includes also many non-HLA genes.
Background
With genotyping chips containing 500,000 and more
single-nucleotide polymorphisms (SNPs) and good
genome coverage, genome-wide association studies
(GWAS) are now widely used to search for susceptibility
genes for complex diseases. For 500,000 statistical tests
in parallel and a nominal level of 0.05, the genome-wide
significance level is 10
-7. Hence, moderately associated
SNPs will have a poor chance of being found at this
level, even in very large samples. Often SNPs are ranked
as a first step to select a “most promising” subset of SNPs
or genes to follow-up. Thus, it is of interest not to
overlook so-called “gene sets” with related genes, e.g., by
pathway, function, or structure, which jointly account for
genomic association to the investigated trait.
Considering p-values for marker selection without
external information may yield many false positives.
Here we focus on two approaches incorporating mole-
cular genetic knowledge, the hierarchical Bayes prior-
itization (HBP) by Lewinger et al. [1] and the gene set
enrichment analysis (GSEA) to GWAS by Wang et al. [2].
We compare the two methods and present ways to
combine them in a GWAS for rheumatoid arthritis.
Methods
Subjects
We applied the strategies to the genome-wide Genetic
Analysis Workshop 16 (GAW16) Rheumatoid Arthritis
(RA) data from the North American Rheumatoid
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Open AccessArthritis Consortium (NARAC). These data include 868
cases and 1194 controls, recruited to Institutional
Review Board-approved protocols and genotyped on
Illumina 550 k SNP chips. All research was carried out in
accordance with the Declaration of Helsinki.
GSEA and HBP
Gene set methods in GWAS are based on an initial
ranking of single SNPs by p-values (here: Cochrane-
Armitage trend test). Then they either identify biologi-
cally relevant “pathways” with functional genetic varia-
tion or they support prioritization of associated
candidate markers or genes. They can be seen as
enhancement to reveal the full spectrum of genes
influencing disease [3].
GSEA was originally developed for gene expression
analysis [4] and recently proposed for GWAS [2]. To
each gene we assigned the maximal test statistic among
all of its SNPs and ranked the genes from largest to
smallest maximum. The enrichment score (ES) for each
gene set measures if its genes are randomly distributed in
the ranking or concentrated on the top. Statistical
significance was assessed by permutations and family-
wise error rate (FWER). The leading edge subset (LES)
was defined as high-scoring gen e so ft h es i g n i f i c a n tg e n e
sets driving the ES.
HBP [1] aims to re-rank markers using prior covariates
on each marker. Regression coefficients for the relation-
ship between prior covariates and observed single
marker association statistics are estimated i) in a
logistic model for the prior probability using marker
distance to genes and gene set information and ii) a
linear model for the strength of association. With the a
posteriori probability of a marker to be associated, a re-
ranked marker list is created. For GSEA we used the
GenGen-package by Wang [5], for HBP we used a
routine for the statistical package R provided by
Lewinger et al. [1].
Gene set and SNP annotation
For gene-to-pathway annotation (GtP), we used a file in
the GenGen-package [5], and for SNP-to-gene annota-
tion (StG), we used files from Illumina. Gene Name
Service (GNS) [6] was used to assure gene name
consistency. We used information from the GtP as
“gene set info” and information about the physical and
functional position of the SNP relative to the nearest
known/predicted gene (e.g., synonymous, coding,
3’UTR) from StG as “SNP info”. We combined gene
sets with a large overlap and excluded sets with less than
11 genes. Finally, 876 gene sets remained.
Strategies of data analysis with GSEA or HBP
I) GSEA alone
GSEA was performed on basic single-SNP association
test statistics. The results are p-values for gene sets and a
list of LES genes.
II) One-step HBP
H B Pw a sp e r f o r m e du s i n gS N Pi n f o r m a t i o na n dg e n es e t
indicators (1 = gene in set, 0 otherwise) as prior
covariates. The result is a ranking of SNPs.
III) Two-step HBP
HBP was performed using SNP information as prior
covariate, followed by HBP additionally using gene set
information. The average a posteriori probability of
association of all remaining genes of the considered set
was used as gene set information for all SNPs of a gene.
The gene-specific probability is the maximum of the a
posteriori probabilities of gene SNPs. The result is a
ranking of SNPs.
IV) HBP followed by GSEA
HBP was performed using SNP information as prior
covariate followed by GSEA using the a posteriori
probabilities of HBP as entry ranking. Results are
p-values for gene sets and a list of LES genes.
Comparing results
GSEA assigns p-values to gene sets, HBP provides SNP
rankings. For comparisons we restricted lists of genes to
100 and lists of gene sets to 20. To compare the most
promising genes, we considered all LES genes of best-
ranked GSEA sets. For Strategies II and III, the highest
ranked SNP per gene was used for a ranked top-gene list.
For Strategies I and IV, we compared the ranking of
identified gene sets according to their p-value; for
Strategies II and III, according to the corresponding
gene set regression parameters of the logistic submodel.
To quantify the overlap of identified genes/gene sets, we
calculated an overlap-index as ratio between observed
different list elements relative to the total number of list
positions llist .
I
nlists
nlists
nelements in lists
llist
=
−
−
∑ 1
1 () .   
This index is 0 if all elements are different, and 1 if all
lists contain the same elements. It may be roughly
interpreted as the chance of an element to appear in
another list as well.
Results
After quality control and trend test, 334 SNPs are
significant at the genome-wide level. They belong to 90
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sets. Due to computer limitations we had to restrict the
number of considered pathways to 100, thus using only
the top 75 genes. This led to only two a priori gene sets
without genes from the HLA-region, and hence to an
influence on the preference towards HLA.
Strategy I (GSEA) yielded 20 gene sets with FWER < 0.05.
The 19 best-ranked gene sets contained the top 100 LES
genes. Strategy IV (HBP+GSEA) resulted in three gene
sets with FWER < 0.05. The two best-ranked gene sets
contained 68 LES genes. Only subset LES genes of the
third gene set could be added to fill up to 100 top genes.
Comparison of most promising genes
A comparison of all four strategies by the ranks of the
top 100 genes with those of the initial ranks is given in
F i g u r e1 .T h eg e n e r a lo v e r l a p - i n d e xf o rt h eg e n el i s t s( I g)
is Ig(I, II, III, IV) = 0.51. The lists we obtain by either of
the two HBP-only strategies are almost identical (Ig(II,
III) = 0.89) and are almost unchanged compared with
the initial list (Ig(II, III, init) = 0.94). In Strategy II only
two new genes appeared; in Strategy III, 11. However, the
LES of the two GSEA strategies highlighted many new
genes. Only 25 or 16 of the initial top 100 genes
(primarily HLA), respectively, are included in the top
100 genes of Strategy I and IV, leading to a low overlap
with the initial list (Ig(I, IV, init) = 0.31). The new LES
genes initially had ranks of up to 21,361. However, the
LES gene lists of these two strategies also differ
remarkably (Ig( I ,I V )=0 . 3 7 ) ,w i t ho n l y3 7g e n e si n
common. The initial ranking reveals the extraordinary
importance of the HLA region. Because HBP changed
this only slightly, both HBP strategies contain more than
80 HLA genes in their top 100 gene lists. Apart from 29
or 19 HLA genes, respectively, the GSEA strategies
include many non-HLA genes, which could be a new
starting point to identify yet unknown additional genes
influencing the disease.
Comparison of gene set ranking
In total, the four top 20 lists comprise 51 different gene
sets. The general overlap-index for the gene sets (Is)i s
Is(I, II, III, IV) = 0.48. Only two gene sets appear in all
four lists: “GO0002460: adaptive immune response” (66
genes) and “hsa04612: antigen processing and presenta-
tion” (61 genes). “hsa04612” contains 22 genes of the
HLA region, while “GO0002560” contains only 3. The
non-HLA genes in this latter set are responsible for
activation or inhibition of immune reactions so that this
identified set is a reasonable candidate for RA. These two
gene sets share only three genes. Interestingly, hsa04612
reached high ranks (third and fourth) only at those
strategies with a GSEA step, but ranks 11 and 17 when
HBP was the final step. On the other hand, GO0002460
ranked between the 11
th and the 19
th rank in all four
strategies. Comparing the top 20 gene sets (Table 1) we
see that Strategy II yields essentially different results,
with list-to-list overlap-indices of Is = 0.25. The remain-
ing strategies comprise 38 gene sets with overlap-index
of Is(I, III, IV) = 0.55. They have 7 gene sets in common,
that are composed of between 11 and 63 genes, but share
pairwise no more than 5 genes. Directly comparing
Strategies I and IV and Strategies II and III, respectively,
results in overlap-indices of Is( I ,I V )=0 . 5 5a n dI s(II, III)
= 0.15. This indicates a more robust ranking of gene sets
by GSEA than by HBP. But even within the top 20 gene
sets of I and IV, the ratio between shared and non-shared
gene sets is 11:18. Changing the number of top gene sets
to consider leads to similar results even though the exact
number of sets identified in all four lists changes (data
not shown). Although the top 100 gene lists of both
strategies with HBP as last step are almost identical, the
top gene sets diverge considerably.
Discussion
GWAS aim to discover new associations and novel
disease genes. For complex diseases, many potentially
interacting genes may be involved. Biological processes,
indicated by gene sets rather than single genes, might
warrant further investigation.
The gene set approaches cannot replace the original
GWAS ranking, but they may identify additional SNPs
within sets that escaped identification due to weak
marginal effects. Locus heterogeneity within one
Figure 1
Gene ranks after applying GSEA, one/two-step HPB
or HBP+GSEA. The top 100 genes were ordered by initial
trend test p-values.
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considered. Gene set approaches can help to structure
results and to distinguish truly associated from unasso-
ciated markers [3]. In this context please note that not all
biological details can be incorporated, especially because
many gene sets are not yet well understood and updates
in databases lag behind knowledge.
In this GWAS, 87 out of the top 100 initial ranked genes
are in the HLA region, a region well known for its role in
RA. The special challenges are to contrast genes within
HLA region, but also to identify non-HLA susceptibility
genes.
Neither GSEA nor HBP is a gold standard for the
integration of gene set information into GWAS. We
found considerable differences in the resulting lists of
the most promising genes and gene sets. The chance of a
gene appearing in more than one of our final gene lists is
only 50%. The same is true for gene sets. Although the
top 100 gene lists of both approaches with only HBP are
almost identical, their lists of gene sets overlapped in
only 3 of the top 20 entries. These heterogenous results
point to methodological differences. GSEA uses the
ranking of genes to find enriched gene sets by summing
ranks, while HBP uses prior gene set information to
change the ranking of SNPs. Hence, GSEA directly leads
to list of most promising gene sets and only builds a
bridge by LES to a list of genes. For HBP, the reverse is
true.
In GSEA, genes with many SNPs are favored by using the
maximal test statistic per gene. In HBP, considering all
markers of a gene may penalize larger genes, because a
true association signal at one marker might be diluted by
all unassociated markers of the gene. GSEA corrects for
linkage disequilibrium structure and for multiple testing
by false-discovery rate or FWER by a computationally
intensive permutation procedure. Neither correction is
considered for the much faster HBP.
Strategies II and III differ only in the way gene set
information is prepared for HBP. In II we used an
indicator for a gene set as “prior” information, for III we
used set-specific weights derived from the observed
association, which is not strictly “prior”.
In comparison with single-SNP analysis, HBP can “be
superior when the proportion of true positive associa-
tions is not too small, as in GWAS with hundreds of truly
associated SNPs” [1]. This can explain the difference in
identified gene sets when compared with GSEA. Lewin-
ger also stated that “when the non-centrality parameters
of the true associations are large enough to be picked by
the raw test statistics there is little to be gained from
prior covariates” [1]. Hence, in this GWAS with 334
genome-wide significant SNPs, the list of most promis-
ing genes did not change for HBP. However, with GSEA
new non-HLA genes were identified. The methods have a
substantial influence on the re-ranked list of top genes.
Strategies I and IV incorporate significance of gene sets,
Table 1: Top gene sets after applying GSEA, one/two-step HPB, or HBP+GSEA
rank Strategy I:
GSEA
Strategy II:
HBP
Strategy III:
HBP+HBP
Strategy IV:
HBP+GSEA
1 hsa04514
a hsa04330
a GO0032393
a hsa04940
b
2 hsa04640 GO0032395
b GO0002504
b hsa04514
a
3 hsa04612
c GO0006956
a GO0048002
b GO0008236
4 hsa04940
b GO0016820 GO0051327 hsa04612
c
5 inflamPathway GO0051028 asbcellPathway
b GO0032395
b
6 th1th2Pathway
a GO0004004 GO0042287 GO0002504
b
7 CSKPathway GO0030554 GO0032395
b GO0048002
b
8 ctla4Pathway
b GO0000279 GO0001569 GO0051249
a
9 blymphoPathway GO0051276 GO0051249 hsa04512
a
10 hsa04650
a GO0019199 GO0002526
b GO0032393
a
11 tcraPathway GO0002460
c GO0006957 th1th2Pathway
a
12 GO0048002
b GO0007160 GO0002460
c hsa04650
a
13 GO0046982 hsa04940
b ctla4Pathway
b hsa04610
14 GO0009405 hsa04612
c hsa00310 GO0002526
b
15 asbcellPathway
b hsa04010 hsa04512
a GO0002460
c
16 hsa04330
a GO0043069 GO00051169 ctla4Path
b
17 GO0006956
a GO0002521 hsa04612
c GO0002443
a
18 GO0002504
b GO0002443
a hsa04320 GO0004175
19 GO0002460
c GO0006281 GO0006643 asbcellPathway
b
20 GO0002526
b GO0009952 GO0016301 GO0003779
ain two strategies.
bin three strategies.
cin all four strategies.
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selecting the top sets, which provide only information
on the magnitude of up-ranking of the genes included in
t h eg e n es e t s .
Note that combining different ranking lists - not
considered here - may lead to a so-called voting
paradoxes.
I ns u m m a r y ,H B Pk e e p st h ep r o m i n e n tr o l eo ft h eH L A -
complex while GSEA enriches the top gene list with non-
HLA genes. Both methods identified the well known
association of HLA and RA. The finding of non-HLA
SNPs by the GSEA suggests that HLA and non-HLA
markers are involved in the disease process. All strategies
included the sets GO0002460 and hsa04612 in their top
20 gene set lists. Thus, all have the ability to recognize
HLA-dominated gene sets as well as other sets. Because
both approaches have their own rationale, the choice of
the method is currently a matter of preference. The main
advantage of HBP over GSEA is that different types of
prior information can be considered, not only gene set
information.
The considered methods were developed to increase
signals jointly for weakly informative markers in
different genes but within one gene set. Because GSEA
uses only the maximal SNP test statistic per gene, several
weakly informative markers within one gene will not be
detected. This problem may be addressed by combining
the SNP statistics with one-gene statistics or by proces-
sing SNP sets instead of gene sets. We concentrated on
single-SNP methods. Please note that depending on the
context, haploype approaches or machine learning
methods might be more advantageous.
Conclusion
Considering prior information, e.g., sets of biological
interrelated genes, is a promising method in GWAS
analysis. Some critical aspects still need to be examined,
including whether to reduce the set of markers and how.
The chosen method has a large impact as the resulting
lists of “most promising” g e n e so rg e n es e t sm a yb ev e r y
different.
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